Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Randomized clinical trial on efficacy of fixed-dose efavirenz/tenofovir/emtricitabine on alternate days versus continuous treatment.

Bellagamba R, Giancola ML, Tommasi C, Piselli P, Tempestilli M, Angeletti C, Zaccarelli M, Ammassari A, Pinnetti C, Gallo AL, Antinori A, Narciso P, Nicastri E; ATAD Study Group.

AIDS. 2019 Mar 1;33(3):493-502. doi: 10.1097/QAD.0000000000002067.

PMID:
30702517
2.

Prevalence and Associated Factors of Neurocognitive Impairment in HIV-Positive Patients on Effective Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Treatment.

Giancola ML, Balestra P, Ammassari A, Ricottini M, Lorenzini P, Angeletti C, Bellagamba R, Tommasi C, Tempestilli M, Zaccarelli M, Pinnetti C, Gallo AL, Antinori A, Narciso P, Nicastri E.

AIDS Res Hum Retroviruses. 2018 Nov;34(11):907-908. doi: 10.1089/AID.2018.0074. Epub 2018 Jul 23. No abstract available.

PMID:
29929374
3.

Dual color fluorescence in situ hybridization (FISH) assays for detecting Mycobacterium tuberculosis and Mycobacterium avium complexes and related pathogens in cultures.

Shah J, Weltman H, Narciso P, Murphy C, Poruri A, Baliga S, Sharon L, York M, Cunningham G, Miller S, Caviedes L, Gilman R, Desmond E, Ramasamy R.

PLoS One. 2017 Apr 11;12(4):e0174989. doi: 10.1371/journal.pone.0174989. eCollection 2017.

4.

Pulmonary tuberculosis followed by sarcoidosis in an HIV-infected patient: A case report and a simplified diagnostic flowchart for diagnosis and treatment of sarcoidosis.

Mencarini P, Bellagamba R, Oliva A, Ghirga P, Giancola ML, Corpolongo A, Ascoli Bartoli T, De Nardo P, Baiocchini A, Del Nonno F, Narciso P, Nicastri E.

Respir Med Case Rep. 2016 Sep 28;19:150-154. eCollection 2016.

5.

Elimination of Mother-To-Child Transmission of HIV Infection: The Drug Resource Enhancement against AIDS and Malnutrition Model.

Liotta G, Marazzi MC, Mothibi KE, Zimba I, Amangoua EE, Bonje EK, Bossiky BN, Robinson PA, Scarcella P, Musokotwane K, Palombi L, Germano P, Narciso P, de Luca A, Alumando E, Mamary SH, Magid NA, Guidotti G, Mancinelli S, Orlando S, Peroni M, Buonomo E, Nielsen-Saines K.

Int J Environ Res Public Health. 2015 Oct 21;12(10):13224-39. doi: 10.3390/ijerph121013224. Review.

6.

Euglycemic Diabetic Ketoacidosis Due to Gastroparesis, A Local Experience.

Legaspi R, Narciso P.

J Ark Med Soc. 2015 Sep;112(5):62-3.

PMID:
26390536
7.

Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by P-glycoprotein.

Tempestilli M, Elisei F, Cimini E, D'Avolio A, Grassi G, Nicastri E, Narciso P, Martini F, Alonzi T, Paolo Pucillo L.

J Antimicrob Chemother. 2014 Jul;69(7):1760-6. doi: 10.1093/jac/dku066. Epub 2014 Mar 19.

PMID:
24648507
8.

Determination of telaprevir in plasma of HCV-infected patients by HPLC-UV.

Tempestilli M, Milano E, D'Offizi G, Montalbano M, D'Avolio A, Gasperi T, Narciso P, Ascenzi P, Pucillo LP.

IUBMB Life. 2013 Sep;65(9):800-5. doi: 10.1002/iub.1197. Epub 2013 Jul 29.

9.

Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors.

Tempestilli M, Gentilotti E, Tommasi C, Nicastri E, Martini F, De Nardo P, Narciso P, Pucillo LP.

Int Immunopharmacol. 2013 Aug;16(4):492-7. doi: 10.1016/j.intimp.2013.05.003. Epub 2013 May 23.

PMID:
23707228
10.

Varicella zoster virus infection presenting as isolated diplopia: a case report.

Pisapia R, Rianda A, Mariano A, Testa A, Galgani S, Vincenzi L, Abdeddaim A, Oliva A, Narciso P.

BMC Infect Dis. 2013 Mar 15;13:138. doi: 10.1186/1471-2334-13-138.

11.

Impact of pre-therapy viral load on virological response to modern first-line HAART.

Santoro MM, Armenia D, Alteri C, Flandre P, Calcagno A, Santoro M, Gori C, Fabeni L, Bellagamba R, Borghi V, Forbici F, Latini A, Palamara G, Libertone R, Tozzi V, Boumis E, Tommasi C, Pinnetti C, Ammassari A, Nicastri E, Buonomini A, Svicher V, Andreoni M, Narciso P, Mussini C, Antinori A, Ceccherini-Silberstein F, Di Perri G, Perno CF.

Antivir Ther. 2013;18(7):867-76. doi: 10.3851/IMP2531. Epub 2013 Jan 23.

PMID:
23343501
12.

Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir.

Gotti D, Cesana BM, Albini L, Calabresi A, Izzo I, Focà E, Motta D, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Brianese N, Quiros-Roldan E, Guaraldi G, Torti C.

HIV Clin Trials. 2012 Sep-Oct;13(5):245-55. doi: 10.1310/hct1305-245.

PMID:
23134625
13.

Ultra-deep sequencing reveals hidden HIV-1 minority lineages and shifts of viral population between the main cellular reservoirs of the infection after therapy interruption.

Rozera G, Abbate I, Ciccozzi M, Lo Presti A, Bruselles A, Vlassi C, D'Offizi G, Narciso P, Giombini E, Bartolini B, Ippolito G, Capobianchi MR.

J Med Virol. 2012 Jun;84(6):839-44. doi: 10.1002/jmv.23292.

PMID:
22996031
14.

Nasal filters in prevention of seasonal rhinitis induced by allergenic pollen grains. Open clinical study.

D'Amato G, Liccardi G, Salzillo A, Russo M, Narciso P, Allegra L.

Eur Ann Allergy Clin Immunol. 2012 Apr;44(2):83-5.

PMID:
22768728
15.

Antiretroviral therapeutic drug monitoring in HIV-infected pregnant women: maternal immunovirological outcome at delivery and during the 18 month follow-up period.

Nicastri E, Ivanovic J, Signore F, Tempestilli M, Bellagamba R, Viscione M, Pisani G, Vallone C, Tommasi C, Gallo AL, De Nardo P, Pucillo PL, Narciso P.

Curr HIV Res. 2012 Oct;10(7):606-13.

PMID:
22762419
16.

The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients.

Santoro MM, Armenia D, Fabeni L, Santoro M, Gori C, Forbici F, Svicher V, Bertoli A, Dori L, Surdo M, Balestra E, Palamara G, Girardi E, Angarano G, Andreoni M, Narciso P, Antinori A, Ceccherini-Silberstein F, Perno CF.

Clin Microbiol Infect. 2012 Aug;18(8):E289-98. doi: 10.1111/j.1469-0691.2012.03905.x. Epub 2012 Jun 8.

17.

Simultaneous determination of lamivudine, lopinavir, ritonavir, and zidovudine concentration in plasma of HIV-infected patients by HPLC-MS/MS.

Notari S, Sergi M, Montesano C, Ivanovic J, Narciso P, Pucillo LP, Ascenzi P.

IUBMB Life. 2012 May;64(5):443-9. doi: 10.1002/iub.1025. Epub 2012 Apr 4.

18.

Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine.

Corpolongo A, De Nardo P, Ghirga P, Gentilotti E, Bellagamba R, Tommasi C, Paglia MG, Nicastri E, Narciso P.

Malar J. 2012 Mar 27;11:91. doi: 10.1186/1475-2875-11-91.

19.

Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.

Santoro MM, Alteri C, Ronga L, Flandre P, Fabeni L, Mercurio F, D'Arrigo R, Gori C, Palamara G, Bertoli A, Forbici F, Salpini R, Boumis E, Tozzi V, Visco-Comandini U, Zaccarelli M, Van Houtte M, Pattery T, Narciso P, Antinori A, Ceccherini-Silberstein F, Perno CF.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1285-93. Epub 2012 Apr 18.

20.

Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.

Svicher V, Alteri C, Montano M, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Allice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Callegaro AP, Capobianchi MR, Carosi G, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Pietro M, Di Santo F, Fabeni L, Fadda G, Galli M, Gennari W, Ghisetti V, Giacometti A, Gori C, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Manca G, Gargiulo F, Martinelli C, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Narciso P, Nozza S, Paolucci S, Pal G, Parisi S, Parruti G, Pignataro AR, Pollicita M, Quirino T, Re MC, Rizzardini G, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Vecchi L, Viscoli C, Vullo V, Zazzi M, Lazzarini A, Perno CF; DIVA group.

New Microbiol. 2012 Jan;35(1):17-25. Epub 2012 Jan 10.

21.

Monophyletic outbreak of Hepatitis A involving HIV-infected men who have sex with men, Rome, Italy 2008-2009.

Bordi L, Rozera G, Scognamiglio P, Minosse C, Loffredo M, Antinori A, Narciso P, Ippolito G, Girardi E, Capobianchi MR; GEAS Group.

J Clin Virol. 2012 May;54(1):26-9. doi: 10.1016/j.jcv.2012.01.009. Epub 2012 Feb 16.

PMID:
22341552
22.

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.

Focà E, Motta D, Borderi M, Gotti D, Albini L, Calabresi A, Izzo I, Bellagamba R, Narciso P, Sighinolfi L, Clò A, Gibellini D, Quiros-Roldan E, Brianese N, Cesana BM, Re MC, Torti C.

BMC Infect Dis. 2012 Feb 14;12:38. doi: 10.1186/1471-2334-12-38.

23.

Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts.

Nozza S, Canducci F, Galli L, Cozzi-Lepri A, Capobianchi MR, Ceresola ER, Narciso P, Libertone R, Castelli P, Moioli M, D'Arminio Monforte A, Castagna A; ICONA Foundation.

J Antimicrob Chemother. 2012 May;67(5):1224-7. doi: 10.1093/jac/dkr600. Epub 2012 Jan 31.

PMID:
22298348
24.

Renal complications in HIV disease: between present and future.

Maggi P, Bartolozzi D, Bonfanti P, Calza L, Cherubini C, Di Biagio A, Marcotullio S, Montella F, Montinaro V, Mussini C, Narciso P, Rusconi S, Vescini F.

AIDS Rev. 2012 Jan-Mar;14(1):37-53. Review.

25.

Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.

Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D'Arrigo R, Van Wesenbeeck L, Scopelliti F, Micheli V, Bruzzone B, Lo Caputo S, Aerssens J, Rizzardini G, Tozzi V, Narciso P, Antinori A, Stuyver L, Perno CF, Ceccherini-Silberstein F.

J Infect Dis. 2012 Feb 15;205(4):557-67. doi: 10.1093/infdis/jir821. Epub 2012 Jan 11.

26.

Total hip replacement infected with Mycobacterium tuberculosis complicated by Addison disease and psoas muscle abscess: a case report.

De Nardo P, Corpolongo A, Conte A, Gentilotti E, Narciso P.

J Med Case Rep. 2012 Jan 10;6:3. doi: 10.1186/1752-1947-6-3.

27.

Molecular diagnosis and species identification of imported malaria in returning travellers in Italy.

Paglia MG, Vairo F, Bevilacqua N, Ghirga P, Narciso P, Severini C, Nicastri E.

Diagn Microbiol Infect Dis. 2012 Feb;72(2):175-80. doi: 10.1016/j.diagmicrobio.2011.09.013. Epub 2011 Nov 10.

PMID:
22078908
28.

A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.

Albini L, Cesana BM, Motta D, Focà E, Gotti D, Calabresi A, Izzo I, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Quiros-Roldan E, Manili L, Guaraldi G, Lapadula G, Torti C.

J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):18-30. doi: 10.1097/QAI.0b013e31823a6124.

PMID:
21992924
29.

Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.

Nicastri E, Tommasi C, Abbate I, Bonora S, Tempestilli M, Bellagamba R, Viscione M, Rozera G, Gallo AL, Ivanovic J, Amendola A, Pucillo L, Di Perri G, Capobianchi MR, Narciso P.

Antivir Ther. 2011;16(6):797-803. doi: 10.3851/IMP1833.

PMID:
21900711
30.

'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.

Alteri C, Santoro MM, Abbate I, Rozera G, Bruselles A, Bartolini B, Gori C, Forbici F, Orchi N, Tozzi V, Palamara G, Antinori A, Narciso P, Girardi E, Svicher V, Ceccherini-Silberstein F, Capobianchi MR, Perno CF.

J Antimicrob Chemother. 2011 Nov;66(11):2615-23. doi: 10.1093/jac/dkr354. Epub 2011 Sep 2.

PMID:
21890537
31.

Deep sequencing of plasma and proviral HIV-1 to establish coreceptor usage: what is the clinical impact of the quasispecies distribution?

Abbate I, Rozera G, Giombini E, D'Offizi G, Nicastri E, Narciso P, Ippolito G, Capobianchi MR.

J Infect Dis. 2011 Sep 15;204(6):971-3; author reply 973-4. doi: 10.1093/infdis/jir427. No abstract available.

PMID:
21849294
32.

Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.

De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, Narciso P, Antinori A, Di Perri G, Prosperi MC, Baldanti F, Micheli V, Zazzi M, Perno CF, Santoro MM; TMC114-C226 study group; ARCA study group.

Antivir Ther. 2011;16(4):489-97. doi: 10.3851/IMP1799.

PMID:
21685536
33.

Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes.

Marazzi MC, Palombi L, Nielsen-Saines K, Haswell J, Zimba I, Magid NA, Buonomo E, Scarcella P, Ceffa S, Paturzo G, Narciso P, Liotta G.

AIDS. 2011 Aug 24;25(13):1611-8. doi: 10.1097/QAD.0b013e3283493ed0.

PMID:
21673553
34.

Cost of surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy.

Massella M, Ivanovic J, Bellagamba R, De Vita R, Fracasso L, Tozzi V, Fragola V, Rizzica M, Narciso P.

Patient Prefer Adherence. 2011;5:223-8. doi: 10.2147/PPA.S16819. Epub 2011 May 17.

35.

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis.

Tommasi C, Bellagamba R, Tempestilli M, D'Avolio A, Gallo AL, Ivanovic J, Nicastri E, Pucillo LP, Narciso P.

Malar J. 2011 May 21;10:141. doi: 10.1186/1475-2875-10-141.

36.

Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection.

Abbate I, Vlassi C, Rozera G, Bruselles A, Bartolini B, Giombini E, Corpolongo A, D'Offizi G, Narciso P, Desideri A, Ippolito G, Capobianchi MR.

AIDS. 2011 Mar 13;25(5):611-7. doi: 10.1097/QAD.0b013e328343489e.

PMID:
21160417
37.

Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.

Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, Schols D, Van Laethem K, Alcaro S, Costa G, Tommasi C, Zaccarelli M, Narciso P, Antinori A, Ceccherini-Silberstein F, Balzarini J, Perno CF.

J Acquir Immune Defic Syndr. 2010 Nov;55(3):336-44. doi: 10.1097/QAI.0b013e3181e6763f.

PMID:
20739898
38.

Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment.

Abbate I, Rozera G, Tommasi C, Bruselles A, Bartolini B, Chillemi G, Nicastri E, Narciso P, Ippolito G, Capobianchi MR.

Clin Microbiol Infect. 2011 May;17(5):725-31. doi: 10.1111/j.1469-0691.2010.03350.x. Epub 2010 Nov 5.

39.

Tolerability of HAART in patients treated during acute HIV infection.

Vlassi C, Corpolongo A, D'Offizi G, Scognamiglio P, Salvatori MF, Fezza R, Narciso P.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):e11-2. doi: 10.1097/QAI.0b013e3181e3b266. No abstract available.

PMID:
20647820
40.

A rare case of severe myopathy associated with etravirine use.

Tommasi C, Tempestilli M, Fezza R, Bellagamba R, Nicastri E, D'offizi G, Pucillo LP, Narciso P.

AIDS. 2010 Apr 24;24(7):1088-90. doi: 10.1097/QAD.0b013e3283382f65. No abstract available.

PMID:
20386384
41.

Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety.

Ivanovic J, Bellagamba R, Nicastri E, Signore F, Vallone C, Tempestilli M, Tommasi C, Mazzitelli L, Narciso P.

AIDS. 2010 Apr 24;24(7):1083-4. doi: 10.1097/QAD.0b013e32833653b2. No abstract available.

PMID:
20386380
42.

Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study.

Prosperi MC, Cozzi-Lepri A, Castagna A, Mussini C, Murri R, Giacometti A, Torti C, Costantini A, Narciso P, Ghinelli F, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group.

Clin Infect Dis. 2010 May 1;50(9):1316-21. doi: 10.1086/651688.

PMID:
20297953
43.

A case of dengue type 3 virus infection imported from Africa to Italy, October 2009.

Nisii C, Carletti F, Castilletti C, Bordi L, Meschi S, Selleri M, Chiappini R, Travaglini D, Antonini M, Castorina S, Lauria FN, Narciso P, Gentile M, Martini L, Di Perri G, Audagnotto S, Biselli R, Lastilla M, Di Caro A, Capobianchi M, Ippolito G.

Euro Surveill. 2010 Feb 18;15(7). pii: 19487.

44.

A case of pulmonary tuberculosis presenting as diffuse alveolar haemorrhage: is there a role for anticardiolipin antibodies?

Marruchella A, Corpolongo A, Tommasi C, Lauria FN, Narciso P.

BMC Infect Dis. 2010 Feb 20;10:33. doi: 10.1186/1471-2334-10-33.

45.

Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir.

Tommasi C, Ceccherini-Silberstein F, D'Arrigo R, Bellagamba R, Tempestilli M, Dessì C, Santoro MM, Forbici F, Nicastri E, Pucillo LP, Perno CF, Narciso P.

Scand J Infect Dis. 2010 Mar;42(3):237-9. doi: 10.3109/00365540903447018.

PMID:
20085429
46.

Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate.

Bellino S, Francavilla V, Longo O, Tripiciano A, Paniccia G, Arancio A, Fiorelli V, Scoglio A, Collacchi B, Campagna M, Lazzarin A, Tambussi G, Din CT, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B.

Rev Recent Clin Trials. 2009 Sep;4(3):195-204. Review.

PMID:
20028332
47.

Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.

Ivanovic J, Nicastri E, Anceschi MM, Ascenzi P, Signore F, Pisani G, Vallone C, Mattia E, Notari S, Tempestilli M, Pucillo LP, Narciso P; Pregnancy And Newborn Clinical Outcome Group in HIV Infection (PANCOH).

Curr HIV Res. 2009 Nov;7(6):620-5.

PMID:
19929798
48.

Archived HIV-1 minority variants detected by ultra-deep pyrosequencing in provirus may be fully replication competent.

Rozera G, Abbate I, Bruselles A, Vlassi C, D'Offizi G, Narciso P, Chillemi G, Prosperi M, Ippolito G, Capobianchi MR.

AIDS. 2009 Nov 27;23(18):2541-3. doi: 10.1097/QAD.0b013e32832fd2e1. No abstract available.

PMID:
19907212
49.

The preventive phase I trial with the HIV-1 Tat-based vaccine.

Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Tripiciano A, Longo O, Bellino S, Francavilla V, Paniccia G, Arancio A, Scoglio A, Collacchi B, Ruiz Alvarez MJ, Tambussi G, Tassan Din C, Palamara G, Latini A, Antinori A, D'Offizi G, Giuliani M, Giulianelli M, Carta M, Monini P, Magnani M, Garaci E.

Vaccine. 2009 Dec 11;28(2):371-8. doi: 10.1016/j.vaccine.2009.10.038. Epub 2009 Oct 29.

PMID:
19879233
50.

Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study.

Narciso P, Bucciardini R, Tozzi V, Bellagamba R, Ivanovic J, Giulianelli M, Scevola S, Palummieri A, Fragola V, Massella M, Fracasso L, De Vita R, Pierro P, Del Maestro A, Mirra M, Weimer L.

AIDS Res Hum Retroviruses. 2009 Oct;25(10):979-87. doi: 10.1089/aid.2009.0029.

PMID:
19795984

Supplemental Content

Loading ...
Support Center